Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI
    • الموضوع:
    • نبذة مختصرة :
      In late 2019, the betacoronavirus SARS-CoV-2 was identified as the viral agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. Coronaviruses Spike proteins are responsible for their ability to interact with host membrane receptors and different proteins have been identified as SARS-CoV-2 interactors, among which Angiotensin-converting enzyme 2 (ACE2), and Basigin2/EMMPRIN/CD147 (CD147). CD147 plays an important role in human immunodeficiency virus type 1, hepatitis C virus, hepatitis B virus, Kaposi's sarcoma-associated herpesvirus, and severe acute respiratory syndrome coronavirus infections. In particular, SARS-CoV recognizes the CD147 receptor expressed on the surface of host cells by its nucleocapsid protein binding to cyclophilin A (CyPA), a ligand for CD147. However, the involvement of CD147 in SARS-CoV-2 infection is still debated. Interference with both the function (blocking antibody) and the expression (knock down) of CD147 showed that this receptor partakes in SARS-CoV-2 infection and provided additional clues on the underlying mechanism: CD147 binding to CyPA does not play a role; CD147 regulates ACE2 levels and both receptors are affected by virus infection. Altogether, these findings suggest that CD147 is involved in SARS-CoV-2 tropism and represents a possible therapeutic target to challenge COVID-19.
    • References:
      Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1305-11. (PMID: 12601063)
      Cell. 2020 May 28;181(5):1016-1035.e19. (PMID: 32413319)
      Science. 2021 Mar 12;371(6534):1152-1153. (PMID: 33514629)
      Nat Med. 2021 Apr;27(4):620-621. (PMID: 33558724)
      Cell Mol Immunol. 2021 Apr;18(4):1061-1063. (PMID: 33633321)
      Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184)
      Signal Transduct Target Ther. 2020 Dec 4;5(1):283. (PMID: 33277466)
      Nat Med. 2021 Apr;27(4):717-726. (PMID: 33664494)
      J Clin Invest. 2019 May 21;129(8):3277-3292. (PMID: 31112527)
      Nat Med. 2005 Aug;11(8):875-9. (PMID: 16007097)
      J Leukoc Biol. 2015 Jul;98(1):33-48. (PMID: 25977287)
      J Virol. 2010 Jan;84(2):1198-205. (PMID: 19864379)
      J Virol. 2005 Dec;79(24):15511-24. (PMID: 16306622)
      Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
      Elife. 2020 Oct 28;9:. (PMID: 33112236)
      Acta Pharm Sin B. 2020 May;10(5):766-788. (PMID: 32292689)
      J Infect Dis. 2005 Mar 1;191(5):755-60. (PMID: 15688292)
      Sci Rep. 2021 Jan 11;11(1):413. (PMID: 33432067)
      Science. 2020 Nov 13;370(6518):856-860. (PMID: 33082293)
      Cell Rep. 2021 Apr 6;35(1):108959. (PMID: 33811811)
      Int J Mol Sci. 2018 Feb 08;19(2):. (PMID: 29419744)
      Int J Mol Sci. 2014 Sep 29;15(10):17411-41. (PMID: 25268615)
      PLoS One. 2012;7(7):e40965. (PMID: 22844419)
      Science. 2020 Nov 13;370(6518):861-865. (PMID: 33082294)
      Antimicrob Agents Chemother. 2020 May 21;64(6):. (PMID: 32205349)
      Int Immunol. 1999 May;11(5):777-86. (PMID: 10330283)
      J Biol Chem. 2002 Jun 21;277(25):22959-65. (PMID: 11943775)
      Circ Res. 2014 Sep 26;115(8):738-50. (PMID: 25149188)
      Mediators Inflamm. 2014;2014:728673. (PMID: 25580061)
      Mol Biol Cell. 2004 Sep;15(9):4148-65. (PMID: 15215314)
      Biomed Pharmacother. 2016 May;80:289-297. (PMID: 27133068)
      Nephrol Dial Transplant. 2015 Jul;30(7):1097-103. (PMID: 25248362)
      Clin J Am Soc Nephrol. 2021 Apr 7;16(4):618-619. (PMID: 33268502)
      Allergy. 2020 Nov;75(11):2829-2845. (PMID: 32496587)
      Proc Natl Acad Sci U S A. 2001 May 22;98(11):6360-5. (PMID: 11353871)
      Matrix Biol. 2015 May-Jul;44-46:138-46. (PMID: 25644103)
      J Biochem. 2016 May;159(5):481-90. (PMID: 26684586)
      Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347)
      Clin Exp Immunol. 2010 Jun;160(3):305-17. (PMID: 20345978)
      Nat Commun. 2020 Oct 12;11(1):5128. (PMID: 33046695)
    • Contributed Indexing:
      Keywords: ACE2; CD147; COVID-19; EMMPRIN; SARS-CoV-2; basigin; entry; infection
    • الرقم المعرف:
      0 (BSG protein, human)
      0 (RNA, Small Interfering)
      0 (Receptors, Virus)
      136894-56-9 (Basigin)
      EC 3.4.17.23 (ACE2 protein, human)
      EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
    • الموضوع:
      Date Created: 20210702 Date Completed: 20210708 Latest Revision: 20210708
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC8226513
    • الرقم المعرف:
      10.3390/cells10061434
    • الرقم المعرف:
      34201214